Industry news
Amicus Therapeutics acquires Scioderm
Amicus Therapeutics has agreed to acquire 100% of the stock of Scioderm Inc. and its drug Zorblisa (SD 101) a treatment for epidermolysis bullosa, a paediatric condition. Scioderm filed a rolling submission for Zorblisa at the FDA in July 2015 and an ongoing Phase III registration trial was initiated in March 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
